Understanding anaemias of the chronically ill
In a nutshell:
New way through which mice starve pathogens of iron
Raises alternative approach to develop treatments for anaemia of chronic disease
When we think of how we fight disease, the image of cells in our immune system fending off microbial invaders often comes to mind. Another strategy our bodies can employ is to cut off the enemy’s supply lines and effectively starve disease-causing microbes of the iron they need to function. However, this tactic can backfire and cause anaemia if the iron-starved state is sustained for too long, a common problem in chronically ill patients. The search for therapies against this anaemia of chronic disease (ACD) could take on new directions thanks to a study published today in Blood. In it, scientists in the Molecular Medicine Partnership Unit, a joint venture of the European Molecular Biology Laboratory (EMBL) and Heidelberg University Clinic, both in Heidelberg, Germany, have found a hitherto unknown way through which mice starve pathogens of iron.
Mammals keep iron out of reach of invading microbes by storing it in cells like macrophages – white blood cells which, among other things, normally ‘recycle’ the iron from red blood cells back into the bloodstream. When the body is under attack, macrophages respond by decreasing levels of their iron-exporter, ferroportin, thereby sequestering the iron. Scientists knew this decrease in ferroportin could be achieved by increasing levels of hepcidin, a hormone which regulates iron levels. But Claudia Guida, a PhD student in the group jointly led by Matthias Hentze at EMBL and Martina Muckenthaler at Heidelberg University Clinic, found that ferroportin can be dialled down independently of hepcidin, by triggering responses from TLR2 and TLR6, two molecules our immune system uses to detect bacterial components.
In response to infection, mice lock up iron (purple) in their macrophages (middle, right). Image from Guida et al. Blood 2015
“Until now, the main approach to develop treatments for anaemia of chronic disease was to look for anti-hepcidin therapies,” says Hentze. “Our findings provide an alternative approach, which is especially relevant because not all patients with anaemia of chronic disease have increased hepcidin levels.”
Why do these cells have two ways of decreasing ferroportin levels? “It could be that this is such an important response, that organisms have evolved a fail-safe, so that if one response fails, they have the other; or it could be a way of broadening the spectrum of what you’re protected against: the hepcidin response might be triggered by some pathogens, and the TLR2/TLR6 response could be activated by others,” says Muckenthaler, “or it could be that this TLR2/TLR6 response we found is a first line of defense, and then the hepcidin response ‘kicks in’ later.”
Hentze, Muckenthaler and colleagues are now investigating exactly what causes ferroportin levels to decrease when TLR2 and TLR6 are activated. As well as informing the search for therapies, this could one day help to develop tests to determine if a patient’s anaemia is caused by problems in his or her TLR2/TLR6 response.
Guida, C., Altamura, S. Klein, F.A., Galy, B., Boutros, M., Ulmer, A.J., Hentze, M.W. & Muckenthaler, M.U. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood, published online 6 February 2015. DOI:10.1182/blood-2014-08-595256
Regulation of iron metabolism and innate immunity are tightly interlinked. The acute phase response to infection and inflammation induces alterations in iron homeostasis that reduce iron supplies to pathogens. The iron-hormone hepcidin is activated by such stimuli causing degradation of the iron exporter ferroportin and reduced iron release from macrophages, suggesting that hepcidin is the crucial effector of inflammatory hypoferremia. Here we report the discovery of an acute inflammatory condition that is mediated by Toll-like receptor (TLR) 2 and TLR6 and which induces hypoferremia in mice injected with TLR ligands. Stimulation of TLR2/TLR6 triggers profound decreases in ferroportin mRNA and protein expression in bone marrow-derived macrophages, liver and spleen of mice without changing hepcidin expression. Furthermore, C326S ferroportin mutant mice with a disrupted hepcidin/ferroportin regulatory circuitry respond to injection of the TLR2/6 ligands FSL1 or PAM3CSK4 by ferroportin down regulation and a reduction of serum iron levels. Our findings challenge the prevailing role of hepcidin in hypoferremia and suggest that rapid hepcidin-independent ferroportin down regulation in the major sites of iron recycling may represent a first line response to restrict iron access for numerous pathogens
EMBL Press Officer, Meyerhofstraße 1, 69117 Heidelberg, Germany
|Tel:||+49 6221 387-8276|
Policy regarding use
Press and Picture Releases
EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.